ArticleAnnals of pediatric endocrinology & metabolism2025
Assessing the ovarian reserve in girls who survived childhood leukemia using anti-Mullerian hormone.
Article in Annals of pediatric endocrinology & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeAcute leukemia is the most common form of malignancy in children; however, there is an absence of data regarding the long-term ovarian reserve of female survivors. The purpose of this investigation was to examine potential discrepancies in anti-Mullerian hormone (AMH) levels among female survivors of pediatric acute leukemia.
methodsA cross-sectional study was conducted on female survivors aged 2 to 18 years who completed gonadotoxic chemotherapy sessions at least 1 year prior to evaluation. Based on Tanner staging, the participants were divided into pre-pubertal and pubertal groups. Serum AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol were assessed.
resultsThree of 36 participants demonstrated low AMH levels in comparison to the adjusted age-reference range, whereas all participants had normal FSH and LH levels. However, the correlation between cumulative dose of cyclophosphamide and AMH level was not statistically significant.
conclusionMeasurement of AMH level may not be beneficial in individuals who have received a cumulative dose of cyclophosphamide less than 5,400 mg/m2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.